Albertine Donker

Chapter 8 296 SUPPLEMENTAL FILE Supplemental Table 1. Performance characteristics of the TSAT/hepcidin ratio to distinguish subjects with IRIDA (n=21) from patients with IDA other than IRIDA (n=39), provided that inflammation is absent, and no iron therapy has been given < 3 months. IRIDA group vs. non-IRIDA group (n=21 and n=39) TSAT/hepcidin ratio: AUC SE of AUC 95% CI of AUC A. Hepcidin <0.5 nM = 0.25 nM Total study population 0.991 0.009 0.973-1.000 Bi-allelic IRIDA group vs. non-IRIDA group 1.000 0.000 1.000-1.000 Mono-allelic IRIDA group vs. non-IRIDA group 0.982 0.019 0.945-1.000 B. Hepcidin <0.5 nM = 0.49 nM (‘worst-case’) Total study population 0.977 0.000 0.931-1.000 Bi-allelic IRIDA group vs. non-IRIDA group 1.000 0.000 1.000-1.000 Mono-allelic IRIDA group vs. non-IRIDA group 0.951 0.048 0.858-1.000 .SE and 95% CI of AUC calculated with SPSS version 22.0 and 95% CI of sensitivity and specificity calculated with Ken Rothman’s Episheet, 2011. 1 Abbreviations: AUC denotes area under the curve; SE, standard error; CI, confidence intervals REFERENCE 1. Kenneth J. Rothman JDB. Spreadsheets for the analysis of epidemiologic data. Version 4 October 2012. Available at: http://krothman. hostbyet2.com/Episheet.xls. Accessed 3 June 2019.